This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Acute Lung Injury industry.
What is the current market size of the acute lung injury industry, and what growth rate is it expected to achieve?
The acute lung injury market size has grown steadily in recent years. It will grow from $2.48 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to awareness campaigns, increase in ICU admissions, smoking and air pollution, hospital-acquired infections, and mortality rate reduction efforts.
The acute lung injury market size is expected to see steady growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to biologics and gene therapies, government funding and grants, the development of precision medicine, regenerative medicine and stem cell therapies, and global health policy reforms. Major trends in the forecast period include development of biologic drugs, wearable and remote monitoring devices, inhalation-based therapies, CRISPR and gene editing technologies and biosensors for real-time analysis.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20704&type=smp
What are the major drivers contributing to the growth of the acute lung injury market?
The rising prevalence of respiratory diseases is expected to propel the growth of the acute lung injury market going forward. Respiratory diseases refer to a group of conditions that affect the lungs and other parts of the respiratory system, leading to difficulty in breathing and impaired lung function. The rising prevalence of respiratory diseases can be due to increased air pollution, smoking, sedentary lifestyles, aging populations, and the impact of viral infections. Respiratory diseases, such as pneumonia, cause acute lung injury by triggering severe inflammation and damaging the alveoli, leading to impaired gas exchange and respiratory distress. For instance, in September 2023, according to the Australian Bureau of Statistics, an Australia-based government agency, the death rate from influenza and pneumonia in the country rose from 31.9 per 100,000 people in 2021 to 42.6 per 100,000 people in 2022, reflecting a substantial increase of approximately 33.54%. Therefore, the rising prevalence of respiratory diseases is driving the growth of the acute lung injury market.
What are the major market segments driving the growth of the acute lung injury industry?
The acute lung injury market covered in this report is segmented –
1) By Injury Type: Direct Injury, Indirect Injury
2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury
2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/acute-lung-injury-global-market-report
What are the key trends shaping the acute lung injury market in the forecast period?
Major companies operating in the acute lung injury market are focusing on developing novel treatments, such as peptide treatments, to sustain their position in the market. Peptide treatment refers to the use of short chains of amino acids (peptides) as therapeutic agents to treat medical conditions. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian-based healthcare company, launched Aviptadil for treating acute respiratory distress syndrome (ARDS). This treatment offers several unique benefits, including potent vasodilatory properties that are 50 times more effective than prostacyclin, a lung protection mechanism that promotes surfactant production by binding to alveolar type II cells, anti-inflammatory effects that inhibit pro-inflammatory cytokines like IL-6 and TNF-alpha, and immunomodulatory action to regulate immune responses in the lungs. Aviptadil has also shown clinical efficacy in improving outcomes for patients with severe viral-related ARDS.
Who are the key market players contributing to the growth of the acute lung injury industry?
Major companies operating in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., MediciNova Inc.
Which regions are leading the growth of the acute lung injury market globally?
North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Acute Lung Injury Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20704
Need Customized Data On Acute Lung Injury Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20704&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
